Cell-Mediated Toxicity of Interleukin-2-Activated Lymphocytes against Autologous and Allogeneic Human Myeloma Cells

1988 ◽  
Vol 80 (4) ◽  
pp. 203-209 ◽  
Author(s):  
Chihiro Shimazaki ◽  
Jens Atzpodien ◽  
David Wisniewski ◽  
Subhash C. Gulati ◽  
Jonathan E. Kolitz ◽  
...  
Keyword(s):  
Interleukin 2 ◽  
Activated Lymphocytes ◽  
Myeloma Cells ◽  
Human Myeloma Cells

Effect of interleukin-2 on the ex vivo growth of human myeloma cells

1989 ◽  
Vol 30 (4) ◽  
pp. 227-232 ◽  
Author(s):  
Dietrich Peest ◽  
Ina de Vries ◽  
Regina Hölscher ◽  
Regine Leo ◽  
Helmuth Deicher
Keyword(s):  
Ex Vivo ◽  
Interleukin 2 ◽  
Myeloma Cells ◽  
Human Myeloma Cells

Effects of an HMG-CoA reductase inhibitor, simvastatin, on human myeloma cells

2004 ◽  
Author(s):  
Takemi Otsuki ◽  
Haruko Sakaguchi ◽  
Tamayo Hatayama ◽  
Tomohiro Fujii ◽  
Takayuki Tsujioka ◽  
...  
Keyword(s):  
Reductase Inhibitor ◽  
Hmg Coa Reductase ◽  
Myeloma Cells ◽  
Hmg Coa Reductase Inhibitor ◽  
Coa Reductase ◽  
Human Myeloma Cells

scholarly journals Identification of immature and mature myeloma cells in the bone marrow of human myelomas

Blood ◽  
1993 ◽  
Vol 82 (2) ◽  
pp. 564-570 ◽  
Author(s):  
MM Kawano ◽  
N Huang ◽  
H Harada ◽  
Y Harada ◽  
A Sakai ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Adhesion Molecules ◽  
Proliferative Activity ◽  
M Protein ◽  
Color Analysis ◽  
Myeloma Cells ◽  
A Cell ◽  
Immature Cells ◽  
Human Myeloma Cells

Abstract With regard to the expression of adhesion molecules, human myeloma cells freshly isolated from bone marrow were heterogeneous. By two- color analysis with anti-VLA-5 antibody (PE staining) and FITC-labeled anti-CD38 antibody, we found all myeloma cells located at CD38-strong positive (CD38++) fraction and identified two subpopulations among these myeloma cells: CD38++ VLA-5-(VLA-5-) myeloma cells and CD38++ VLA- 5+ (VLA-5+) myeloma cells. To clarify the biologic character of these two subpopulations, the morphology, in vitro proliferative activity and in vitro M-protein secretion were examined in each fraction isolated by the purification procedure or a cell sorter. Morphologic examination showed that VLA-5- myeloma cells were mostly immature or plasmablastic and VLA-5+ cells were mature myeloma cells. Furthermore, VLA-5- myeloma cells proliferated markedly in vitro and responded to interleukin 6 (IL- 6), a growth factor for myeloma cells, while VLA-5+ myeloma cells showed very low uptakes of 3H-thymidine and no responses to IL-6 but secreted higher amounts of M-protein (immunoglobulin) in vitro significantly. Therefore, we could clarify here heterogeneity of human myeloma cells in the bone marrow with regard to the expression of VLA- 5, one of integrin adhesion molecules; VLA-5- myeloma cells were proliferative immature cells and VLA-5+ cells were mature myeloma cells.

An IL-6 receptor antagonist for IL-6 activity on human myeloma cells

Cytokine ◽  
1994 ◽  
Vol 6 (5) ◽  
pp. 564
Author(s):  
J.P.J. Brakenhoff ◽  
F.D. de Hon ◽  
M. Ehlers ◽  
J. Grötzinger ◽  
C. Clement ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Myeloma Cells ◽  
Human Myeloma Cells

scholarly journals Percutaneous Exposures of volunteers to polychromatic light (480-3400 nm) trigger systemic mechanism of the human myeloma cells growth delay without any effect on bortezomib cytotoxicity in vitro

LASER THERAPY ◽  
2019 ◽  
Vol 28 (3) ◽  
pp. 164-170
Author(s):  
Natalia V. Kalmykova ◽  
Anna V. Shcherbanyuk ◽  
Sergei I. Moiseev ◽  
Natalia V. Bichkova ◽  
Natalia I. Davidova ◽  
...  
Keyword(s):  
Growth Delay ◽  
Myeloma Cells ◽  
Systemic Mechanism ◽  
Polychromatic Light ◽  
Human Myeloma Cells

Novel Immunosuppressant Agents Targeting Activated Lymphocytes by Biocompatible MPC Polymer Conjugated with Interleukin-2

2007 ◽  
Vol 39 (2) ◽  
pp. 103-110 ◽  
Author(s):  
N. Chiba ◽  
M. Ueda ◽  
T. Shimada ◽  
H. Jinno ◽  
J. Watanabe ◽  
...  
Keyword(s):  
Interleukin 2 ◽  
Activated Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document